News

A combination of telemedicine and in-person visits led to a nearly 6% increase in electronic health record work for primary care physicians.

These data allow for a basis for additional research and possible interventions to address psoriasis patients’ demodicosis risk.

Daniel Gaudet, MD, PhD, discusses SHASTA-2 data and what cardiologists could learn from the forthcoming 48-week MUIR trial data from EAS 2024.

FDA issued a CRL the abbreviated new drug application of ketamine, which had sought to enhance accessibility to the limited drug supply.

Abbott's Esprit BTK System was shown to significantly reduce risk of ischemic events in patients with PAD versus angioplasty over 1 year.

FDA approves mavorixafor (XOLREMDI) for WHIM syndrome, the first approved treatment for the rare disease.

Barratt explained findings from the phase 2b ORIGIN trial of atacicept and how it compares to current standard therapies in IgAN and other agents in the pipeline.

The announcement by Dermavant followed positive findings from the ADORING trials on tapinarof and an open label extension for children aged 2 - 17.

A new study found a 2-week mindfulness-based intervention for patients with psoriasis does not improve skin status—it only helps the mind.

This observational cohort study looked at the link between obesity and eczema, highlighting regional differences in the skin disease and obesity’s interdependence.

A single-center assessment showed patients with glomerulonephritis may face a heightened risk of primary disease recurrence up to 1 year after transplant.

In an interview, Larry Ereshefsky, PharmD, discussed other conditions brilaroxazine could potentially treat other than schizophrenia due to its mechanism.

KDpredict uses age, sex, eGFR, and albuminuria to calculate 1-5 year risk of kidney failure and death in chronic kidney disease, outperforming the kidney failure risk equation.

A higher TRV was significantly associated with cerebrovascular disease and persistent albuminuria in children with SCD across two large cohorts.

Both vaccine type and period mediated the risk of uveitis after COVID-19 vaccination in patients with a history of the ocular inflammatory event.

During this discussion, Ohuabunwa discussed additional takeaways from her ACP conference talk on postdischarge care and other tips for internal medicine physicians.

A meta-analysis of 12 trials suggests catheter ablation for atrial fibrillation reduces heart failure events in HFrEF patients but not in HFpEF.

Many parents experience high levels of isolation, loneliness, and burnout, feeling like there is no one to talk to about their struggles in their daily lives.

Results showed a negative correlation between serum Gd-IgA1 and kidney function but found no association with several validated IgAN prognostic risk factors.

This discussion with Ohuabunwa was held at the ACP conference and covered inpatient geriatrics assessment tips for internal medicine physicians.

Larry Ereshefsky, PharmD, discussed the effects of brilaroxazine on inflammatory cytokines and neuroinflammation and how this can impact future schizophrenia treatment.

Areas with socioeconomic disadvantage often face concentrated poverty, poor walkability, and few healthcare facilities, creating challenges in eye care follow-up.

Matthew Nudy, MD, discusses a trio of meta-analyses examining the effects of intensive blood pressure control on various targets.

FDA approves the generic equivalent of Narcan HCI Nasal Spray—naloxone hydrochloride (Naloxone HCI)—for an emergency treatment option for an opioid overdose.

This analysis highlighted several trends in search volume regarding eczema, including correlations with weather and climate.

The extent of stigma significantly differs based on disease visibility and severity among children with chronic skin disorders.

The second in our 3-part quiz series based on the NLA's 2024 update to their 2019 scientific statement on use of lipoprotein(a) in clinical practice focuses on recommendations for patients.

Eyenovia assessed the duration of effect of the lowest deliverable dose of tropicamide and phenylephrine hydrochloride ophthalmic spray 1%/2.5% in a phase 4 study.